Paul W Rothlauf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2845813/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host and Microbe, 2021, 29, 44-57.e9.	5.1	937
2	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Science Immunology, 2020, 5, .	5.6	811
3	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, 2021, 184, 2332-2347.e16.	13.5	784
4	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host and Microbe, 2021, 29, 477-488.e4.	5.1	700
5	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nature Medicine, 2020, 26, 1422-1427.	15.2	450
6	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host and Microbe, 2020, 28, 475-485.e5.	5.1	380
7	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32105-32113.	3.3	192
8	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host and Microbe, 2020, 28, 465-474.e4.	5.1	156
9	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20803-20813.	3.3	154
10	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
11	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell Reports, 2021, 36, 109364.	2.9	109
12	A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	54
13	A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants. Proceedings of the United States of America, 2021, 118, .	3.3	22
14	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. MBio, 2022, 13, e0344221.	1.8	19
15	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. SSRN Electronic Journal, 2020, , 3606354.	0.4	16
16	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. MBio, 2022, 13, e0337721.	1.8	14
17	Detection of Bourbon Virus-Specific Serum Neutralizing Antibodies in Human Serum in Missouri, USA. MSphere, 2022, 7, .	1.3	9
18	Noninvasive Immuno-PET Imaging of CD8+ T Cell Behavior in Influenza A Virus-Infected Mice. Frontiers in Immunology, 2021, 12, 777739.	2.2	8

#	Article	IF	CITATIONS
19	Saliva enhances infection of gingival fibroblasts by herpes simplex virus 1. PLoS ONE, 2019, 14, e0223299.	1.1	5